Closing the personalized medicine information gap

HER2 test documentation practice

Ilia L. Ferrusi, Craig C. Earle, Maureen Trudeau, Natasha B. Leighl, Eleanor Pullenayegum, Hoa Khong, Jeffrey S Hoch, Deborah A. Marshall

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

CONCLUSIONS: Despite a universal testing policy, the rate of centralized HER2 test documentation was lower than expected and related to disease severity. Differences in regional reporting likely reflect ascertainment bias inherent to centralized pathology reporting rather than testing access. Improved HER2 reporting is encouraged for cancer registration, quality-of-care measurement, and program evaluation.

BACKGROUND: Uncertainty about human epidermal growth factor receptor-2 (HER2) testing practice in Canada continues to hinder efforts to improve personalized medicine. Pathologists routinely perform HER2 assessment for all tumors > 1 cm, and pathology is reported centrally to the provincial cancer registry.

OBJECTIVES: To understand patterns of HER2 test documentation for early-stage breast cancer (BC) patients in Ontario's centralized pathology reporting system.

STUDY DESIGN: Retrospective cohort study of central HER2 test documentation in early-stage BC patients diagnosed in 2006-2007.

METHODS: Cohort and staging information was derived from cancer registry and admissions data. Linkage across administrative databases provided data on surgical and radiologic treatment, sociodemographic factors, diagnosis setting, and comorbidities. Pathology reports from the provincial cancer registry were reviewed for HER2 testing, hormone receptor, and grade. Unadjusted and adjusted odds ratios were calculated to determine factors related to HER2 documentation.

RESULTS: A HER2 test was documented for 66% of 13,396 patients. HER2 documentation was associated with stage, hormone receptor, and tumor grade documentation. Higher stage and grade at diagnosis were also associated with HER2 documentation. All models suggested variable regional documentation patterns. Documentation did not differ by sociodemographic factors, presence of comorbidities, or surgical procedure.

Original languageEnglish (US)
Pages (from-to)838-844
Number of pages7
JournalThe American journal of managed care
Volume19
Issue number1
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Precision Medicine
Documentation
Pathology
Registries
Neoplasms
Comorbidity
human ERBB2 protein
Hormones
Breast Neoplasms
Quality of Health Care
Program Evaluation
Ontario
Uncertainty
Canada
Cohort Studies
Retrospective Studies
Odds Ratio
Databases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ferrusi, I. L., Earle, C. C., Trudeau, M., Leighl, N. B., Pullenayegum, E., Khong, H., ... Marshall, D. A. (2013). Closing the personalized medicine information gap: HER2 test documentation practice. The American journal of managed care, 19(1), 838-844.

Closing the personalized medicine information gap : HER2 test documentation practice. / Ferrusi, Ilia L.; Earle, Craig C.; Trudeau, Maureen; Leighl, Natasha B.; Pullenayegum, Eleanor; Khong, Hoa; Hoch, Jeffrey S; Marshall, Deborah A.

In: The American journal of managed care, Vol. 19, No. 1, 01.01.2013, p. 838-844.

Research output: Contribution to journalArticle

Ferrusi, IL, Earle, CC, Trudeau, M, Leighl, NB, Pullenayegum, E, Khong, H, Hoch, JS & Marshall, DA 2013, 'Closing the personalized medicine information gap: HER2 test documentation practice', The American journal of managed care, vol. 19, no. 1, pp. 838-844.
Ferrusi IL, Earle CC, Trudeau M, Leighl NB, Pullenayegum E, Khong H et al. Closing the personalized medicine information gap: HER2 test documentation practice. The American journal of managed care. 2013 Jan 1;19(1):838-844.
Ferrusi, Ilia L. ; Earle, Craig C. ; Trudeau, Maureen ; Leighl, Natasha B. ; Pullenayegum, Eleanor ; Khong, Hoa ; Hoch, Jeffrey S ; Marshall, Deborah A. / Closing the personalized medicine information gap : HER2 test documentation practice. In: The American journal of managed care. 2013 ; Vol. 19, No. 1. pp. 838-844.
@article{7e0f5e3481de4f3f90ba35635005fa27,
title = "Closing the personalized medicine information gap: HER2 test documentation practice",
abstract = "CONCLUSIONS: Despite a universal testing policy, the rate of centralized HER2 test documentation was lower than expected and related to disease severity. Differences in regional reporting likely reflect ascertainment bias inherent to centralized pathology reporting rather than testing access. Improved HER2 reporting is encouraged for cancer registration, quality-of-care measurement, and program evaluation.BACKGROUND: Uncertainty about human epidermal growth factor receptor-2 (HER2) testing practice in Canada continues to hinder efforts to improve personalized medicine. Pathologists routinely perform HER2 assessment for all tumors > 1 cm, and pathology is reported centrally to the provincial cancer registry.OBJECTIVES: To understand patterns of HER2 test documentation for early-stage breast cancer (BC) patients in Ontario's centralized pathology reporting system.STUDY DESIGN: Retrospective cohort study of central HER2 test documentation in early-stage BC patients diagnosed in 2006-2007.METHODS: Cohort and staging information was derived from cancer registry and admissions data. Linkage across administrative databases provided data on surgical and radiologic treatment, sociodemographic factors, diagnosis setting, and comorbidities. Pathology reports from the provincial cancer registry were reviewed for HER2 testing, hormone receptor, and grade. Unadjusted and adjusted odds ratios were calculated to determine factors related to HER2 documentation.RESULTS: A HER2 test was documented for 66{\%} of 13,396 patients. HER2 documentation was associated with stage, hormone receptor, and tumor grade documentation. Higher stage and grade at diagnosis were also associated with HER2 documentation. All models suggested variable regional documentation patterns. Documentation did not differ by sociodemographic factors, presence of comorbidities, or surgical procedure.",
author = "Ferrusi, {Ilia L.} and Earle, {Craig C.} and Maureen Trudeau and Leighl, {Natasha B.} and Eleanor Pullenayegum and Hoa Khong and Hoch, {Jeffrey S} and Marshall, {Deborah A.}",
year = "2013",
month = "1",
day = "1",
language = "English (US)",
volume = "19",
pages = "838--844",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "1",

}

TY - JOUR

T1 - Closing the personalized medicine information gap

T2 - HER2 test documentation practice

AU - Ferrusi, Ilia L.

AU - Earle, Craig C.

AU - Trudeau, Maureen

AU - Leighl, Natasha B.

AU - Pullenayegum, Eleanor

AU - Khong, Hoa

AU - Hoch, Jeffrey S

AU - Marshall, Deborah A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - CONCLUSIONS: Despite a universal testing policy, the rate of centralized HER2 test documentation was lower than expected and related to disease severity. Differences in regional reporting likely reflect ascertainment bias inherent to centralized pathology reporting rather than testing access. Improved HER2 reporting is encouraged for cancer registration, quality-of-care measurement, and program evaluation.BACKGROUND: Uncertainty about human epidermal growth factor receptor-2 (HER2) testing practice in Canada continues to hinder efforts to improve personalized medicine. Pathologists routinely perform HER2 assessment for all tumors > 1 cm, and pathology is reported centrally to the provincial cancer registry.OBJECTIVES: To understand patterns of HER2 test documentation for early-stage breast cancer (BC) patients in Ontario's centralized pathology reporting system.STUDY DESIGN: Retrospective cohort study of central HER2 test documentation in early-stage BC patients diagnosed in 2006-2007.METHODS: Cohort and staging information was derived from cancer registry and admissions data. Linkage across administrative databases provided data on surgical and radiologic treatment, sociodemographic factors, diagnosis setting, and comorbidities. Pathology reports from the provincial cancer registry were reviewed for HER2 testing, hormone receptor, and grade. Unadjusted and adjusted odds ratios were calculated to determine factors related to HER2 documentation.RESULTS: A HER2 test was documented for 66% of 13,396 patients. HER2 documentation was associated with stage, hormone receptor, and tumor grade documentation. Higher stage and grade at diagnosis were also associated with HER2 documentation. All models suggested variable regional documentation patterns. Documentation did not differ by sociodemographic factors, presence of comorbidities, or surgical procedure.

AB - CONCLUSIONS: Despite a universal testing policy, the rate of centralized HER2 test documentation was lower than expected and related to disease severity. Differences in regional reporting likely reflect ascertainment bias inherent to centralized pathology reporting rather than testing access. Improved HER2 reporting is encouraged for cancer registration, quality-of-care measurement, and program evaluation.BACKGROUND: Uncertainty about human epidermal growth factor receptor-2 (HER2) testing practice in Canada continues to hinder efforts to improve personalized medicine. Pathologists routinely perform HER2 assessment for all tumors > 1 cm, and pathology is reported centrally to the provincial cancer registry.OBJECTIVES: To understand patterns of HER2 test documentation for early-stage breast cancer (BC) patients in Ontario's centralized pathology reporting system.STUDY DESIGN: Retrospective cohort study of central HER2 test documentation in early-stage BC patients diagnosed in 2006-2007.METHODS: Cohort and staging information was derived from cancer registry and admissions data. Linkage across administrative databases provided data on surgical and radiologic treatment, sociodemographic factors, diagnosis setting, and comorbidities. Pathology reports from the provincial cancer registry were reviewed for HER2 testing, hormone receptor, and grade. Unadjusted and adjusted odds ratios were calculated to determine factors related to HER2 documentation.RESULTS: A HER2 test was documented for 66% of 13,396 patients. HER2 documentation was associated with stage, hormone receptor, and tumor grade documentation. Higher stage and grade at diagnosis were also associated with HER2 documentation. All models suggested variable regional documentation patterns. Documentation did not differ by sociodemographic factors, presence of comorbidities, or surgical procedure.

UR - http://www.scopus.com/inward/record.url?scp=84925558640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925558640&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 838

EP - 844

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 1

ER -